Study Comparing Atomizerd Midazolam & Fentanyl and Dexmedomidine for Procedural Sedation in Adult and Pediatric Patient (2 to 60 Years Old)

NCT ID: NCT07166666

Last Updated: 2025-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2026-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the depth of sedation, as well as onset, and recovery times, satisfaction of sedation , adverse events associated with Atomized Midazolam \& Fentanyl and Dexmedetomidine during procedural sedation in a diverse population spanning from 2 to 60 years old at these three prominent Omani healthcare facilities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sedation Analgesia Assessment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

midazolame $ fentanyl

use as compare between two group

Group Type OTHER

atomizer

Intervention Type DEVICE

use atomizer to provide the medication in procedure sedation

rescue medication

Intervention Type DRUG

will be used as rescue if the atomizer medication not fully sedated

Midazolam

Intervention Type DRUG

Intranasal administration for procedural sedation.

fentanyl

Intervention Type DRUG

Intranasal administration for procedural sedation.

dexetomidate

use as compare to other group

Group Type OTHER

atomizer

Intervention Type DEVICE

use atomizer to provide the medication in procedure sedation

rescue medication

Intervention Type DRUG

will be used as rescue if the atomizer medication not fully sedated

Dexmedetomidine

Intervention Type DRUG

Intranasal administration for procedural sedation.

Placabo

Intervention Type DRUG

use atomizer to provide the placebo in procedure sedation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

atomizer

use atomizer to provide the medication in procedure sedation

Intervention Type DEVICE

rescue medication

will be used as rescue if the atomizer medication not fully sedated

Intervention Type DRUG

Midazolam

Intranasal administration for procedural sedation.

Intervention Type DRUG

fentanyl

Intranasal administration for procedural sedation.

Intervention Type DRUG

Dexmedetomidine

Intranasal administration for procedural sedation.

Intervention Type DRUG

Placabo

use atomizer to provide the placebo in procedure sedation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged 2 to 60 years.
2. Patients undergoing EM procedures requiring sedation.

Exclusion Criteria

1. Patients with contraindications to any of the sedation agents being studied.
2. Patients with a history of adverse reactions or allergies to the study medications.
3. Drug interactions: Patients taking certain medications that may interact adversely with the study medications.
4. Drug Abuser
5. Pregnancy and breastfeeding
6. Patients with significant cardiovascular or respiratory compromise.
7. Patients with nasal disorder (nasal trauma, epistaxis)
8. Patients unable to provide informed consent or those with cognitive impairment.
9. Patients who are \< 2 year of age or \> 60 year of age.
10. Patient underwent procedure sedation for imaging
Minimum Eligible Age

2 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oman Medical Speciality Board

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ghaliya Al Noofli

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

saud al bulashi, MD

Role: STUDY_DIRECTOR

MOH/ oman

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

dr.Suad al baluish

Muscat, , Oman

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Oman

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ghaliy khamis al noofli, MD

Role: CONTACT

+96895751564

ahoud abdullah al saidi, MD

Role: CONTACT

+96892903021

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MOH/ oman

Identifier Type: OTHER

Identifier Source: secondary_id

MoH/CSR/24/28497

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.